Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

TMBMKGB-10Y | A complete U.K. 10 Year Gilt bond overview by MarketWatch. View the latest bond prices, bond market news and bond rates.